SCHEMBL15071827

SCHEMBL15071827

Cc1ccc(CON2C(=O)c3ccccc3C2=O)nc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
MAPT P10636 1/20 0.47
GAA P10253 1/20 0.45
ALDH1A1 P00352 5/20 0.43
HTT P42858 2/20 0.43
VDR P11473 1/20 0.43
RECQL P46063 1/20 0.43
HPGD P15428 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
ATM Q13315 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
TP53 P04637 1/20 0.40
PKM P14618 1/20 0.40
STAT3 P40763 1/20 0.40
STAT1 P42224 1/20 0.40
RAB9A P51151 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13477401 0.82 KMT2A (0.47) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL4347031 0.82 MEN1 (0.47) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL2935415 0.82 MEN1 (0.48) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL4345352 0.82 ALDH1A1 (0.44) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL13140630 0.79 MEN1 (0.43) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL2219482 0.78 ALDH1A1 (0.58) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL2937635 0.78 ALDH1A1 (0.46) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL5528619 0.78 MEN1 (0.73) MEN1KMT2AMAPTGAAALDH1A1
SCHEMBL3430183 0.75 HSD17B10 (0.63) MEN1KMT2AMAPTALDH1A1HTT
SCHEMBL6921729 0.75 MEN1 (0.48) MEN1KMT2AMAPTGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140187780-A1 6,11-BRIDGED BIARYL MACROLIDES ENANTA PHARMACEUTICALS, INC. (US) 2014-07-03 US disclosed
US-20130165641-A1 6,11-BRIDGED BIARYL MACROLIDES ENANTA PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165641-A1 6,11-BRIDGED BIARYL MACROLIDES CYP2B6, CYP2D6, ABCB11 MEN1 3695/4885KMT2A 3432/4885MAPT 3727/4885
US-20140187780-A1 6,11-BRIDGED BIARYL MACROLIDES CYP2B6, CYP2D6, ABCB11 MEN1 3695/4885KMT2A 3432/4885MAPT 3727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.